Detected ·

Aura Biosciences

——

Aura Biosciences (NASDAQ: AURA) closed an underwritten public offering of approximately $299.4 million gross proceeds to advance its precision therapies for solid tumors, with lead candidate bel-sar in late-stage development for early choroidal melanoma.

Amount
—
Stage
—
Event
Funding round
Detected
2026-05-07 20:14:05 UTC
Signal ID
4f2f983b-1cf3-4e77-a338-f8682c567d82

As the API returns it

{
  "id": "4f2f983b-1cf3-4e77-a338-f8682c567d82",
  "created_at": "2026-05-07T20:14:05.455367Z",
  "company_name": "Aura Biosciences",
  "company_website_url": "www.aurabiosciences.com",
  "company_linkedin_url": "https://www.linkedin.com/company/aurabiosciences",
  "event_type": "funding",
  "funding_amount": null,
  "funding_currency": null,
  "funding_stage": null,
  "message": "*Aura Biosciences (NASDAQ: AURA) closed an underwritten public offering of approximately $299.4 million gross proceeds to advance its precision therapies for solid tumors, with lead candidate bel-sar in late-stage development for early choroidal melanoma.*"
}

Latest rounds